13 completed, 6 recruiting, 3 active not recruiting, 3 not yet recruiting. 22 Phase 2, 6 Phase 3, 5 Phase 1, 2 Not applicable, 2 Phase 4.
Follow testosterone cypionate: new trials by email Literature Review of testosterone cypionate trials Research Report on testosterone cypionate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance Testosterone cypionate - Prostate Cancer, Hypogonadism, Male | Phase 4 | Not yet recruiting | University of Miami | 35 | 2026-08-31 | 2026-07-22 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-10-30 |
| The Anabolic Effect of Testosterone on Pelvic Floor Muscles Testosterone cypionate, Placebo - Stress Urinary Incontinence, Menopause | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 30 | 2025-02-15 | 2026-06-26 |
| Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Biopsy, Bone Scan, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 3 | 2024-12-19 | 2026-08-07 |
| Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 69 | 2024-05-21 | 2026-07-21 |
| Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC Testosterone Cypionate, Sipuleucel-T - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Yale University | 26 | 2023-12-20 | 2026-09-10 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2023-10-04 | 2026-01-14 |
| Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial) Testosterone Cypionate, Placebo - Pain, Opioid Use | Phase 2 | Completed | Brigham and Women's Hospital | 36 | 2022-11-15 | 2026-04-15 |
| Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair Testosterone cypionate, Placebos - Rotator Cuff Tears | Phase 2 / Phase 3 | Withdrawn | Orthopedic Institute, Sioux Falls, SD | 2021-08-01 | 2022-03-15 | |
| Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) Testosterone Cypionate, Darolutamide - Prostate Cancer | Phase 2 | Completed | Latin American Cooperative Oncology Group | 51 | 2021-06-09 | 2026-08-28 |
| Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone Best Practice, Quality-of-Life Assessment, Questionnaire Administration - Hypogonadism, Malignant Urinary System Neoplasm | Phase 1 | Active not recruiting | Emory University | 56 | 2021-01-25 | 2026-05-26 |
| Effect of Transgender Therapy on Muscle, Fat and Tissue Receptors testosterone cypionate, Estradiol Valerate - Gender Incongruence, Transgenderism | Terminated | St. Louis University | 4 | 2020-10-06 | 2024-01-08 | |
| Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy Testosterone cypionate - Prostate Cancer | Phase 2 | Completed | Hospital Sirio-Libanes | 20 | 2020-09-22 | 2022-08-03 |
| Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Testosterone cypionate, Enzalutamide, Testosterone enanthate - Castration Resistant Metastatic Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 150 | 2020-08-19 | 2026-07-17 |
| COMbination of Bipolar Androgen Therapy and Nivolumab Testosterone cypionate, Nivolumab - Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 45 | 2018-09-05 | 2024-02-20 |
| Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment - Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Completed | University of Washington | 36 | 2018-08-29 | 2025-09-29 |
Showing 20 of 32. Sign in to see all of them.
Prostatic Neoplasms (14) · Hypogonadism (5) · Eunuchism (2) · Gender Dysphoria (2) · Anorexia Nervosa (1) · Back Pain (1) · Bone Diseases (1) · Bone Resorption (1) · Central Nervous System Diseases (1) · Endocrine System Diseases (1) · Fatigue (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Gonadal Disorders (1) · Male Urogenital Diseases (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (10) · Brigham and Women's Hospital (2) · University of Washington (2) · VA Office of Research and Development (2) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Enhanced Emirates Limited (1) · Hospital Sirio-Libanes (1) · Hospital de Clinicas de Porto Alegre (1) · Latin American Cooperative Oncology Group (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Men's Health Boston (1) · Orthopedic Institute, Sioux Falls, SD (1) · Roswell Park Cancer Institute (1)
United States (26) · Brazil (3) · Canada (1) · United Arab Emirates (1)
Samuel Denmeade, MD (8) · Michael Schweizer (2) · Sandeep Dhindsa, MD (2) · Abraham Morgentaler, MD (1) · Alberto J Pacheco, BA (1) · Bruce Kava, MD (1) · Craig W Spellman, DO (1) · Diogo Assed Bastos (1) · Grace Huang, MD (1) · Joseph W Kim, MD (1) · Joshua F Yarrow, PhD MS BS (1) · Keith M Baumgarten, MD (1) · Kenneth Ogan, MD (1) · Laura Sena, MD, PhD (1) · Madhusmita Misra, MD (1)
PMID 29248236, PMID 32624280, PMID 33383350, PMID 33617303, PMID 33735389, PMID 35027313, PMID 35027909, PMID 35938545, PMID 38167882
P30CA015704 (1), P30CA138292 (1), P50CA097186 (1), P50CA272391 (1), R01CA184012 (1), R01DK136904 (1), U10CA180820 (1)